Biotechnology - Rare diseases, Esbriet


Current filters:

Rare diseasesEsbriet

Popular Filters

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData


Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Germany’s IQWIG negative on InterMune’s Esbriet


US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top